Mutual of America Capital Management LLC Purchases 2,451 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mutual of America Capital Management LLC increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 1.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,384 shares of the biopharmaceutical company’s stock after acquiring an additional 2,451 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Halozyme Therapeutics were worth $5,120,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Mercer Global Advisors Inc. ADV lifted its stake in shares of Halozyme Therapeutics by 0.7% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 48,612 shares of the biopharmaceutical company’s stock worth $1,955,000 after acquiring an additional 337 shares during the period. Fifth Third Bancorp lifted its stake in shares of Halozyme Therapeutics by 4.7% in the fourth quarter. Fifth Third Bancorp now owns 11,793 shares of the biopharmaceutical company’s stock worth $474,000 after acquiring an additional 534 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 25.2% in the fourth quarter. Lazard Asset Management LLC now owns 3,177 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 639 shares during the period. Virginia Retirement Systems ET AL lifted its stake in shares of Halozyme Therapeutics by 2.2% in the first quarter. Virginia Retirement Systems ET AL now owns 33,000 shares of the biopharmaceutical company’s stock worth $1,316,000 after acquiring an additional 700 shares during the period. Finally, Louisiana State Employees Retirement System lifted its stake in shares of Halozyme Therapeutics by 1.9% in the first quarter. Louisiana State Employees Retirement System now owns 36,900 shares of the biopharmaceutical company’s stock worth $1,598,000 after acquiring an additional 700 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on HALO. The Goldman Sachs Group lifted their price objective on Halozyme Therapeutics from $48.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, May 26th. StockNews.com lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Finally, SVB Leerink started coverage on Halozyme Therapeutics in a research note on Monday, May 23rd. They issued an “outperform” rating and a $52.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average target price of $52.33.

Halozyme Therapeutics Stock Down 1.4 %

Shares of NASDAQ:HALO opened at $49.50 on Monday. The company has a market capitalization of $6.83 billion, a PE ratio of 16.56, a price-to-earnings-growth ratio of 0.78 and a beta of 1.20. The company has a debt-to-equity ratio of 3.03, a current ratio of 8.85 and a quick ratio of 8.42. The business has a fifty day moving average price of $46.22 and a two-hundred day moving average price of $40.49. Halozyme Therapeutics, Inc. has a 1 year low of $31.36 and a 1 year high of $52.98.

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.02). The business had revenue of $117.30 million during the quarter, compared to the consensus estimate of $128.25 million. Halozyme Therapeutics had a net margin of 92.23% and a return on equity of 132.71%. The firm’s revenue for the quarter was up 31.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.34 EPS. Analysts forecast that Halozyme Therapeutics, Inc. will post 2.06 earnings per share for the current year.

Halozyme Therapeutics Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.